ProQR (PRQR) AI Stock Analysis

• Market Cap: $166.45M
• Dividend Yield: N/A
• Average Volume (3M): 534.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.87
• Revenue Growth: -11.99%
• EPS Growth: -42.04%
• Country: US
• Employees: 166
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 105,345,190
• 10 Day Avg. Volume: 796,312
• 30 Day Avg. Volume: 534,757
• PEG Ratio: 2.63
• Price to Book (P/B): 2.36
• Price to Sales (P/S): 11.05
• P/FCF Ratio: -5.53
• Enterprise Value/Market Cap: 0.28
• Enterprise Value/Revenue: 3.02
• Enterprise Value/Gross Profit: 3.02
• Enterprise Value/Ebitda: -1.24
• 1Y Price Target: $8.33
• Price Target Upside: 455.33% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.53
• Revenue Forecast (FY): $20.38M

• Rating: 42 Neutral
• Price Target: $1.50 ▲(0.00% Upside)
• Action: Reiterated Date: 12/03/25
• Date: Action: Reiterated 12/03/25

ProQR's overall stock score is primarily impacted by its financial performance and technical analysis. The company's significant financial challenges, particularly in profitability and cash flow, are the most critical factors. Technical indicators suggest bearish momentum, and the valuation reflects ongoing losses. These factors collectively contribute to a lower overall stock score.

Positive Factors

Gross Profit Margin

A 100% gross profit margin indicates the platform can cover direct product costs and, if commercialized, offer strong unit economics. This durable advantage can support long-term margin recovery as fixed R&D and SG&A scale down versus potential product revenue.

Manageable Leverage

A modest debt-to-equity ratio (0.25) gives ProQR financial flexibility and lower refinancing risk compared with highly leveraged peers. This structural balance sheet strength helps sustain funding for multi-year clinical programs without immediate pressure to service large debt loads.

Pipeline Progress and Partnership Funding

Positive Phase 1 safety/PK data and selection of additional development candidates strengthen the R&D pipeline and de-risk program progression. Material milestone payments from Eli Lilly provide non-dilutive financing, extending runway into mid-2027 and enabling multiple development and partnering paths.

Negative Factors

Severe Negative Profitability

A trailing net margin of -240% signals structural operating losses far exceeding revenues. Sustained hyper-negative margins indicate the company must achieve clinical and commercial milestones or secure significant external funding to reach breakeven, posing a long-term viability risk.

Negative Operating and Free Cash Flow

Persistent negative operating and free cash flow constrain internal funding for R&D and operations, increasing reliance on partnerships, milestone payments, or equity/debt financing. This structural cash burn elevates dilution and refinancing risk over the 2–6 month horizon and beyond.

Declining Revenue and Rising Operating Losses

Recent quarterly revenue declines alongside increased operating losses reflect a structural gap between commercial income and expense base. Unless offset by new partnerships, cost reductions, or successful program readouts, this trend pressures runway and may force strategic, potentially dilutive, financing decisions.

ProQR Business Overview & Revenue Model

Company Description

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

How the Company Makes Money

ProQR primarily generates revenue through various streams including government grants, strategic partnerships, and collaborations with pharmaceutical companies that seek to develop and commercialize their RNA therapies. The company also focuses on licensing its technology to other entities in the biotech and pharmaceutical sectors, which provides additional income. Furthermore, ProQR may receive milestone payments and royalties from partnered projects that progress successfully through clinical trials and into commercialization. Its revenue model is heavily reliant on the successful development and approval of its therapeutics, which can lead to significant financial returns through product sales and licensing agreements.

ProQR Financial Statement Overview

Summary

ProQR faces significant financial challenges, particularly in terms of profitability and cash flow generation. Despite a strong gross profit margin and manageable debt level, the negative net income and cash flow issues pose risks. The biotechnology industry is inherently volatile, and ProQR's financials reflect the typical high-risk, high-reward nature of the sector.

Income Statement

ProQR's income statement reveals significant challenges with profitability. The company has consistently reported negative net profit margins, with the TTM (Trailing-Twelve-Months) net profit margin at -240.63%. Revenue growth has been negative recently, indicating declining sales. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Despite these challenges, the gross profit margin remains high at 100%, suggesting that the company can cover its cost of goods sold effectively.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.25 in the TTM period, indicating a manageable level of debt relative to equity. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is not explicitly calculated, but the company's equity position appears stable relative to its assets, suggesting some financial stability despite profitability issues.

Cash Flow

ProQR's cash flow statement highlights challenges in generating positive cash flow. The operating cash flow and free cash flow are both negative, although there has been some improvement in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to net income. However, the free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is somewhat aligned with net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.56M	18.91M	6.51M	3.59M	1.33M	1.03M
Gross Profit	15.56M	18.91M	6.51M	3.59M	1.33M	1.03M
EBITDA	-37.87M	-24.12M	-24.10M	-56.46M	-54.95M	-48.44M
Net Income	-42.57M	-27.76M	-28.12M	-64.42M	-60.74M	-46.56M
Balance Sheet
Total Assets	124.35M	167.96M	152.31M	171.32M	209.58M	120.80M
Cash, Cash Equivalents and Short-Term Investments	106.88M	149.41M	131.37M	94.78M	187.52M	92.79M
Total Debt	16.49M	17.22M	21.80M	21.97M	60.37M	41.94M
Total Liabilities	67.28M	79.40M	106.59M	104.64M	96.35M	51.61M
Stockholders Equity	57.07M	88.56M	45.72M	67.06M	113.83M	69.85M
Cash Flow
Free Cash Flow	-49.41M	-37.81M	20.18M	-69.22M	-26.50M	-47.98M
Operating Cash Flow	-48.78M	-36.39M	21.55M	-68.51M	-26.01M	-47.06M
Investing Cash Flow	-3.28M	-4.07M	4.28M	-702.00K	-425.00K	-924.00K
Financing Cash Flow	70.19M	70.28M	-2.27M	-30.89M	136.83M	14.50M

ProQR Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Neutral. The current price of 1.5 is above the 20-day moving average (MA) of 1.50, below the 50-day MA of 1.73, and below the 200-day MA of 2.07, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 50.24 is Neutral, neither overbought nor oversold. The STOCH value of 73.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRQR.

ProQR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVIR	58 Neutral	$380.48M	-2.74	-37.98%	―	―	14.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OABI	50 Neutral	$253.36M	-2.98	-22.37%	―	3.36%	5.15%
HRTX	48 Neutral	$226.24M	-9.96	―	―	12.60%	58.23%
PRQR	42 Neutral	$166.45M	-3.46	-99.45%	―	-11.99%	-42.04%
CDXS	42 Neutral	$92.13M	-1.36	-114.26%	―	-17.87%	14.42%

ProQR Corporate Events

ProQR Reports Positive AX-0810 Phase 1 Data, Advances Rett and MASH Candidates, and Outlines 2026 Pipeline Plans

On January 8, 2026, ProQR reported encouraging initial Phase 1 data for its lead candidate AX-0810, showing no serious safety issues and pharmacokinetics in line with preclinical findings after four weeks of dosing in the first cohort of healthy volunteers, with target engagement data expected in the first half of 2026 and plans to add a patient cohort thereafter. The company also selected development candidates AX-2402 for Rett syndrome and AX-2911 for MASH based on robust preclinical proof-of-concept data, highlighted non-clinical results suggesting disease-modifying potential versus existing approaches, and noted that milestone payments from its collaboration with Eli Lilly in 2025 support a cash runway into mid-2027 as it advances its Axiomer platform and executes its 2026 development and partnering agenda.

The most recent analyst rating on (PRQR) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.

ProQR Reports Q3 2025 Financial Results Amid Revenue Decline

ProQR Therapeutics N.V. announced its financial results for the third quarter and the nine-month period ending September 30, 2025. The company reported a decrease in revenue compared to the previous year, with €2,882,000 for the quarter and €11,218,000 for the nine-month period. Operating costs increased, leading to a higher operating loss of €11,284,000 for the quarter and €34,349,000 for the nine months. The results reflect ongoing challenges in the biotechnology sector, impacting ProQR’s financial performance and highlighting the need for strategic adjustments to improve profitability.

The most recent analyst rating on (PRQR) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.

ProQR Advances AX-0810 into Clinical Trials for Cholestatic Diseases

On November 3, 2025, ProQR Therapeutics hosted a virtual analyst and investor event to discuss its lead pipeline program, AX-0810, which is entering a first-in-human clinical trial targeting NTCP in cholestatic diseases. The event highlighted the company’s strategic overview and corporate outlook, emphasizing the establishment of safety, pharmacokinetics, and a biomarker roadmap for proof of target engagement. This development positions ProQR at the forefront of RNA editing medicines, particularly in neurological applications, and underscores its commitment to addressing unmet medical needs in various diseases.

The most recent analyst rating on (PRQR) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.